Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
BMC Cancer
|
May 7, 2021
Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301
Norihito Okumura, Junichi Soh, Hiroyuki Suzuki, et al.
Cureus
|
July 24, 2025
Retreatment With EGFR-Tyrosine Kinase Inhibitor After Disease Progression Following Gefitinib Induction and Chemoradiotherapy in EGFR-Mutant Stage III Non-small Lung Cancer: An Efficacy and Safety Analysis of the LOGIK0902/OLCSG0905 Study
Sho Saeki, Katsuyuki Hotta, Shinya Sakata, et al.
Journal of Cancer Research and Clinical Oncology
|
July 12, 2008
Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience
Katsuyuki Hotta, Katsuyuki Kiura, Nagio Takigawa, et al.
International Journal of Clinical Oncology
|
May 9, 2022
Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801
Shinobu Hosokawa, Eiki Ichihara, Daijiro Harada, et al.
International Journal of Clinical Oncology
|
February 5, 2025
Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study
Katsuyuki Hotta, Sho Saeki, Shinya Sakata, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 19, 2011
Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007
Nagio Takigawa, Katsuyuki Kiura, Yoshihiko Segawa, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 31, 2014
A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801
Keisuke Aoe, Nagio Takigawa, Katsuyuki Hotta, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 24, 2014
A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501
Naoyuki Nogami, Nagio Takigawa, Katsuyuki Hotta, et al.
Thoracic Cancer
|
January 12, 2021
Novel prospective umbrella-type lung cancer registry study for clarifying clinical practice patterns: CS-Lung-003 study protocol
Kazuya Nishii, Masaaki Inoue, Hideto Obata, et al.
Plos One
|
May 19, 2023
Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201
Hiromasa Yamamoto, Junichi Soh, Norihito Okumura, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
BMC Cancer
|
May 7, 2021
Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301
Norihito Okumura, Junichi Soh, Hiroyuki Suzuki, et al.
Cureus
|
July 24, 2025
Retreatment With EGFR-Tyrosine Kinase Inhibitor After Disease Progression Following Gefitinib Induction and Chemoradiotherapy in EGFR-Mutant Stage III Non-small Lung Cancer: An Efficacy and Safety Analysis of the LOGIK0902/OLCSG0905 Study
Sho Saeki, Katsuyuki Hotta, Shinya Sakata, et al.
Journal of Cancer Research and Clinical Oncology
|
July 12, 2008
Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience
Katsuyuki Hotta, Katsuyuki Kiura, Nagio Takigawa, et al.
International Journal of Clinical Oncology
|
May 9, 2022
Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801
Shinobu Hosokawa, Eiki Ichihara, Daijiro Harada, et al.
International Journal of Clinical Oncology
|
February 5, 2025
Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study
Katsuyuki Hotta, Sho Saeki, Shinya Sakata, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 19, 2011
Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007
Nagio Takigawa, Katsuyuki Kiura, Yoshihiko Segawa, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 31, 2014
A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801
Keisuke Aoe, Nagio Takigawa, Katsuyuki Hotta, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 24, 2014
A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501
Naoyuki Nogami, Nagio Takigawa, Katsuyuki Hotta, et al.
Thoracic Cancer
|
January 12, 2021
Novel prospective umbrella-type lung cancer registry study for clarifying clinical practice patterns: CS-Lung-003 study protocol
Kazuya Nishii, Masaaki Inoue, Hideto Obata, et al.
Plos One
|
May 19, 2023
Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201
Hiromasa Yamamoto, Junichi Soh, Norihito Okumura, et al.
Page
of 6